Skip to content
Catalyst

PapersPMID:39256461

Comparative study of safflower yellow adjuvant to conventional treatment regimen and conventional treatment regimen on diabetic nephropathy.

Scientific reports2024The record ↗

findings
2
compound
1
endpoints
2
  1. Finding, moderate evidencelowersFasting blood glucose
  2. Finding, moderate evidenceraisesClinical effective rate (composite responder rate)
Study, every finding
meta-analysis
  • “The result showed that the level of FBG was significantly decreased in safflower yellow adjuvant to conventional treatment group compared with conventional treatment group (MD = 0.40, 95%CI 0.05 to 0.75; Fig. 3A).”
    Effect
    0.4 mean difference, 95% CI 0.05 to 0.75
    Population
    Patients with early diabetic nephropathy and type 2 diabetes; 14 pooled randomised trials of safflower yellow added to conventional treatment versus conventional treatment, with background drugs given to both arms in many trials
  • “The results suggested that the total efficacy rate in safflower yellow adjuvant to conventional treatment group was higher than that in conventional treatment group (RR = 1.28, 95%CI 1.21 to 1.36; Fig. 3E).”
    Effect
    1.28 risk ratio, 95% CI 1.21 to 1.36
    Population
    Patients with early diabetic nephropathy and type 2 diabetes; 15 pooled randomised trials of safflower yellow added to conventional treatment versus conventional treatment, with background drugs given to both arms in many trials

Study record

Design
meta-analysis
Species
human
Population
Patients with early diabetic nephropathy and type 2 diabetes; 28 Chinese randomised trials of safflower yellow (extract of safflower petals) added to conventional treatment
Participants
2,251
Comparator
no treatment
Duration
not reported
Endpoints measured
13